Revista Española de Medicina Nuclear e Imagen Molecular, published by Elsevier España SLU, stands as a vital resource in the field of Radiology, Nuclear Medicine, and Molecular Imaging. With an ISSN of 2253-654X, this journal is committed to disseminating high-quality research and advancements in clinical practices, aiming to bridge the gap between theoretical research and application in healthcare. Operating since 2012, it features a robust archive of peer-reviewed articles and case studies, although it currently holds a Q4 ranking in the Scopus category, indicating significant potential for growth and influence within the academic community. The journal is indexed in Scopus, with a rank of 255 out of 333, placing it in the 23rd percentile, which underlines the need for increased contributions from researchers eager to enhance its standing. While it is not an open-access journal, its availability through libraries and institutions ensures that a wide audience can access critical findings and innovations in the rapidly evolving field of nuclear medicine. As we look towards the convergence period from 2012 to 2024, Revista Española de Medicina Nuclear e Imagen Molecular aspires to fortify its role as a cornerstone for collaboration and advancement in nuclear imaging and radiology.

Medicine Nucleaire-Imagerie Fonctionnelle et Metabolique is a prominent journal published by Elsevier France-Editions Scientifiques Medicales Elsevier, dedicated to the specialized fields of nuclear medicine and functional imaging. With an ISSN of 0928-1258 and an E-ISSN of 1878-6820, this esteemed publication has been a crucial platform for the dissemination of research and developments in the discipline since its inception in 1993. Covering a wide array of topics within biophysics, radiological and ultrasound technology, and radiology, the journal currently holds a Q4 category ranking in these fields, reflecting its significance within the academic community. Although there are currently no open access options available for readers, the journal caters to a niche audience of researchers, professionals, and students who seek to enhance their understanding of metabolic imaging and its applications. The 2023 Scopus ranks indicate its position as an emerging source of knowledge in a competitive landscape, making it an important resource for the latest studies and innovations in nuclear medicine.

NUCLEAR MEDICINE AND BIOLOGY, published by Elsevier Science Inc, is a premier journal dedicated to advancing the fields of nuclear medicine and molecular biology. Since its inception in 1986, this journal has served as a vital platform for the dissemination of high-quality research, with a clear focus on the innovative applications of nuclear techniques in biological settings. It is categorized in the Q3 tier for both Cancer Research and Molecular Medicine, and Q2 for Radiology, Nuclear Medicine and Imaging, highlighting its significant standing within these disciplines. The journal's Scopus rankings reflect its strong impact, placing it in the top quartile of its categories, particularly in Radiology, Nuclear Medicine, and Imaging. Researchers, professionals, and students alike will find this an invaluable resource for contemporary research findings and methodologies in nuclear medicine and its biological applications. Access to the journal is provided through subscription, ensuring that quality content remains available to its wide-ranging audience.

Nuclear Medicine and Molecular Imaging, published by SPRINGER HEIDELBERG, stands as a pivotal platform in the interdisciplinary field of radiology and nuclear medicine, focusing on innovative research and developments from 2010 to 2024. With its ISSN 1869-3474 and E-ISSN 1869-3482, this journal aims to disseminate advanced studies that explore the diagnostic and therapeutic applications of nuclear medicine technologies. Operating from Germany, it has positioned itself in the Q3 category within the Radiology, Nuclear Medicine and Imaging sector, showcasing its relevance among peer journals, with a Scopus rank of #204 out of 333. This journal not only serves as an essential resource for researchers and practitioners eager to stay abreast of modern methodologies and findings but also underscores the crucial advancements in molecular imaging techniques. Although currently not an open-access journal, it doesn't detract from its mission to promote knowledge exchange among academia and the medical community, thus paving the way for innovative solutions and improved patient care in nuclear medicine.

CLINICAL NUCLEAR MEDICINE is a premier journal dedicated to the field of nuclear medicine, published by Lippincott Williams & Wilkins. With a history of excellence since its inception in 1978, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to deepen their understanding of this rapidly evolving discipline. The journal holds a commendable Q2 ranking in both Medicine (miscellaneous) and Radiology, Nuclear Medicine and Imaging, reflecting its significant impact on advancing clinical practices and research. While currently not offered as an open-access publication, CLINICAL NUCLEAR MEDICINE ensures rigorous peer review and high-quality publications, contributing to the broad dissemination of cutting-edge studies and reviews. With its comprehensive scope encompassing both diagnostic and therapeutic nuclear medicine applications, researchers around the globe turn to this journal to stay informed and inspire innovations in patient care for the years leading up to 2024 and beyond.

ANNALS OF NUCLEAR MEDICINE is a prominent academic journal dedicated to the field of nuclear medicine, published by Springer. With a rich publication history dating back to 1987 and continuing through 2024, this journal serves as a vital resource for researchers and practitioners interested in the latest developments in nuclear imaging, radiopharmaceuticals, and therapeutic applications. Ranked in the second quartile (Q2) for both Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging categories in 2023, it maintains a strong position in the academic community, with an impressive Scopus rank of #104 out of 333 in its field, placing it in the 68th percentile. The journal is not open access but offers a range of access options through institutional or individual subscriptions, ensuring that critical research findings reach a wide audience. By fostering high-quality, peer-reviewed articles, ANNALS OF NUCLEAR MEDICINE plays a crucial role in advancing the understanding and practical application of nuclear medicine techniques, making it an essential journal for professionals and students aiming to stay at the forefront of this evolving discipline.

CANCER IMAGING, published by BMC, stands as a leading open-access journal in the realms of oncology and medical imaging, significantly contributing to the advancement of cancer research since its inception in 2000. With an impressive impact across multiple domains—most notably ranking Q1 in prestigious categories such as Medicine (miscellaneous), Oncology, and Radiology—this journal ensures high visibility and influence within the academic community. As of 2023, it is recognized in various Scopus rankings, securing top positions in the fields of Radiology, Nuclear Medicine, and Imaging, alongside Radiological and Ultrasound Technology. The journal's commitment to open-access publication, adopted in 2014, enhances accessibility for researchers, healthcare professionals, and students alike, fostering an inclusive environment for sharing critical advancements and innovative methodologies in cancer imaging. Set in the vibrant landscape of the United Kingdom, CANCER IMAGING continues to play a vital role in elucidating the complexities of cancer diagnostics and treatment, establishing itself as an essential resource for those pursuing excellence in cancer care and research.

NUKLEARMEDIZIN-NUCLEAR MEDICINE is a prestigious journal published by Georg Thieme Verlag KG, focusing on pivotal advancements in the fields of Nuclear Medicine, Radiology, and Imaging. Established in 1959, this journal has served as a critical platform for disseminating innovative research, reviews, and clinical guidelines until its anticipated convergence in 2024. With an ISSN of 0029-5566 and an E-ISSN of 2567-6407, NUKLEARMEDIZIN is acknowledged in the academic community as a Q3 category journal within Medicine (miscellaneous) and Radiology, Nuclear Medicine, and Imaging as of 2023, highlighting its ongoing contribution to the interdisciplinary dialogue in healthcare. Although the journal does not currently offer open access, it remains accessible to professionals and students through various academic databases, ensuring that cutting-edge knowledge in this growing field is shared widely. Researchers interested in the latest methods and technologies in Nuclear Medicine will find NUKLEARMEDIZIN a valuable resource for enhancing their work and understanding the complexities of modern imaging modalities.

The American Journal of Nuclear Medicine and Molecular Imaging (ISSN: 2160-8407), published by E-CENTURY PUBLISHING CORP, is a distinguished platform for the dissemination of cutting-edge research in the fields of nuclear medicine and molecular imaging. With a commitment to advancing scientific inquiry and clinical applications, this journal serves as a vital resource for researchers, clinicians, and students dedicated to exploring innovative imaging modalities, radiopharmaceuticals, and their applications in diagnosing and treating various medical conditions. Although currently not available as an open-access journal, this publication plays a crucial role in fostering academic dialogue and collaboration within the medical community. Its diverse range of topics and expert contributions underscore its impact in bridging the gap between research findings and clinical practice, making it an essential read for anyone interested in the rapidly evolving landscape of nuclear medicine and imaging technologies.

NUCLEAR MEDICINE REVIEW is a distinguished journal in the field of radiology, nuclear medicine, and imaging, published by VIA MEDICA in Poland. Since its transition to an open access format in 1999, this journal has been dedicated to promoting the dissemination of knowledge and research findings across a global audience. With a focus on innovative approaches and advancements in nuclear medicine, it aims to serve as a key resource for researchers, professionals, and students who are working to further the understanding of nuclear imaging and its applications. In 2023, the journal was classified in the Q3 category within Radiology, Nuclear Medicine and Imaging, and Q4 in the broader category of Medicine (miscellaneous), highlighting its growing reputation in the academic community. As of the latest assessments, the journal has been ranked #235 out of 333 in its field according to Scopus metrics, reflecting its commitment to excellence and the relevance of its published works. The NUCLEAR MEDICINE REVIEW is a pivotal platform for those engaged in cutting-edge research, providing insights that drive the evolution of medical imaging and therapeutic techniques.